Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × loncastuximab tesirine × 1 year × Clear all

NCT05296070 2025-09-30

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell, Marginal Zone